Sai Life Sciences has officially released its investor presentation for the quarter ended June 30, 2026. The presentation highlights key financial metrics including ₹554 crore in revenue, a 12% year-on-year growth, and ₹73 crore in Profit After Tax (PAT), marking a 22% year-on-year increase. The document also provides updates on business segments, operational milestones, and strategic priorities.
Sai Life Sciences Presents Q1 FY27 Performance
Sai Life Sciences Limited has submitted its investor presentation for the first quarter of the Financial Year 2027 (Q1 FY27), which concluded on June 30, 2026. The document was formally submitted to the National Stock Exchange of India Limited and BSE Limited on August 07, 2026. This presentation offers a comprehensive overview of the company’s performance and strategic direction.
Financial Highlights
The Q1 FY27 snapshot reveals robust financial growth. Key figures include:
- Revenue: ₹554 crore, showing a 12% year-on-year (YoY) growth.
- Material Margin: ₹409 crore, up 15% YoY.
- EBITDA: ₹148 crore, representing an 18% YoY growth.
- PAT (Profit After Tax): ₹73 crore, with a significant 22% YoY growth.
The revenue mix for the quarter was divided between CDMO (60%) and CRO (40%). Capacity utilization stood at 65%, with Capex Incurred at ₹263 crore.
Consolidated Financial Performance
Further details on consolidated financial highlights are provided:
- Revenue (₹ Cr): ₹496 crore in Q1FY26, growing to ₹554 crore in Q1FY27 (12% YoY Growth).
- Material Margin (₹ Cr) & Margin (%): ₹355 crore (72%) in Q1FY26, increasing to ₹409 crore (74%) in Q1FY27 (15% YoY Growth).
- EBITDA* (₹ Cr) & Margin (%): ₹125 crore (25%) in Q1FY26, rising to ₹148 crore (27%) in Q1FY27 (18% YoY Growth).
- PAT (₹ Cr) & Margin (%): ₹60 crore (12%) in Q1FY26, advancing to ₹73 crore (13%) in Q1FY27 (22% YoY Growth).
The company stated, “The quarter reflects continued progress across both businesses and our longer-term strategic priorities. We remain confident in our ability to sustain our long-term revenue growth guidance of 15-20% and EBITDA range of 28-30%.”
Business Updates
Key business updates include:
- Discovery: Grew by 24% YoY, with strengthening large pharma collaborations and integrated service delivery to 65% of customers.
- CMC: Production commenced for 3 of 4 molecules added to the pipeline last year. An end-to-end collaboration spanning discovery to commercialization was expanded with a top-tier pharma relationship.
- Key Priorities Ahead: Establishing an integrated peptide platform, adding a Drug Product facility, and building a future-ready scientific organization.
Other Business Updates
Sai Life Sciences achieved the EcoVadis Platinum Rating 2026, placing it among the top 1% of companies globally for sustainability performance. Capex progress is largely on schedule, and a new 100,000 sq. ft. R&D facility at Genome Valley, Hyderabad, has been operationalized. The company also successfully executed commercial-scale Photo Flow Chemistry and commissioned a High-Throughput Experimentation (HTE) platform.
Company Overview and Strengths
Sai Life Sciences operates as an integrated CRDMO with 27 years of expertise, serving over 300+ global clients, including 19 of the top 25 global pharma companies. Its expansive infrastructure includes facilities across Hyderabad, Bidar, Manchester, and Boston. The company is focused on innovation-led growth in modalities like Peptides, ADCs, and Oligos, leveraging digital transformation, automation, and AI/ML.
Key highlights emphasize its position as the Fastest growing Indian CRDMO over the last 5 years, a 26% CAGR in revenue growth, and a 100% successful track record of regulatory inspections.
Operational Excellence
The company’s operations are underpinned by global standards in Quality Assurance, Sustainability Leadership (including 100% renewable energy at its Bidar site), and Safety & EHS Leadership. This includes embedded process safety and validated containment levels down to 1 µcg/ m³.
Financial Statement Annexure
A detailed Consolidated Statement of Profit and Loss for Q1FY27, Q4FY26, and Q1FY26 is provided. For Q1FY27, Revenue from operations stood at ₹554 crore, with a Total Income of ₹558 crore. Expenses included cost of materials (₹145 crore) and employee benefits (₹180 crore). EBITDA was reported at ₹148 crore with an EBITDA Margin of 27%, leading to a Profit After Tax of ₹73 crore.
Source: BSE
